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LETTER TO THE EDITOR
Evaluating the efficacy of pre-operative fistula risk assessment
We read with great interest the recent manuscript by Roberts and
colleagues which introduced a pre-operative fistula risk metric for
patients undergoing a pancreatoduodenectomy (PD).1 As a post-
operative pancreatic fistula (POPF) is the most common compli-
cation after PD, the authors argue that such a tool could be useful
for identifying at-risk patients, and adjusting the management of
their care accordingly. Their study presents a thoughtful and bal-
anced report regarding the merits and deficiencies of their
approach; however, we believe this manuscript introduces issues
worthy of further discourse, particularly, POPF risk assessment.
As risk scores become more prevalent, it is imperative to ensure
their fidelity through a rigorous external validation process prior
to ubiquitous acceptance. This requires multi-centre assessment
with a sizable number of patients. With this in mind, we
attempted to externally validate the model proposed by Roberts.
Pre-operative risk scores were derived for 1345 patients (four
institutions and six surgeons) undergoing PD and authenticated
using the web-based calculator.1 Patient characteristics evaluated
for the model were body mass index (BMI) and pancreatic duct
diameter. POPFs were graded in accordance with ISGPF standards
and designated as either biochemical or clinically relevant fistulae
(CR-POPF). Risk scores were entered into logistic regression
models with POPF and CR-POPF as the outcomes of interest.
The overall POPF rate was 27.4%, of which, 46.1% were clini-
cally relevant (12.6% overall). The median BMI and pancreatic
duct diameter measurements were 25.7 kg/m2 and 4 mm, respec-
tively. The mean and median risk score was 16.0 and 13.0. Regres-
sion analysis identified the risk score as a significant predictor for
overall POPF and CR-POPF (P < 0.001). Sensitivity and specificity
for POPF prediction was 12.20% and 95.80%. The positive and
negative predictive values (PPV and NPV) were 52.3% and 74.3%.
Sensitivity and specificity for CR-POPF prediction was 0% and
99.7%; moreover, the PPV and NPV was 0% and 87.3%. Calibra-
tion of both models was deemed unacceptable by Hosmer–
Lemeshow χ2 testing (POPF: P < 0.001; CR-POPF: P = 0.029). The
c-statistics for predicting POPF and CR-POPF were 0.689 and
0.666, respectively (P < 0.001).
This analysis demonstrates that the risk score proposed by
Roberts and colleagues is not sufficient to replace other estab-
lished metrics for fistula risk assessment. Fistula incidence was
predicted in only 12.2% of cases, whereas the absence of fistula
was correctly predicted 74.3% of the time. Although the absence
of CR-POPF was predicted with high accuracy (NPV = 99.7%),
the positive prediction of these fistula – arguably more important
in regards to preoperative counselling – was poor (PPV = 0%).
The area under the curve (AUC) values were <0.7 for the predic-
tion of POPF and CR-POPF – lower than in the original report by
Roberts – as well as the externally validated Fistula Risk Score
(FRS); the latter was validated using a nearly identical cohort.2,3
Furthermore, Hosmer–Lemeshow tests produced P-values <0.05,
which signified a poor model fit.
In addition to concerns about the model’s predictive capacity,
we have other reservations. First, disease pathology categori-
zation paired pancreatic cancer with ampullary cancer and
cholangiocarcinoma, which contrasts with findings in the litera-
ture that indicate greater fistula risk with the latter pathologies.
Pathologies other than pancreatitis and pancreatic cancer usually
correlate with soft glands and non-dilated ducts, unfavourable
scenarios for anastomotic connection.4 Perhaps, confounding
factors caused patients with pancreatic, ampullary and bile duct
cancers to have similar fistula rates during univariate analysis.
Clustering pathologies based upon pre-existing literature and
clinical intuition would be preferable, and may have led to the
inclusion of pathologic diagnosis in the model’s construct, as with
the FRS.2,5
Of greater concern is Roberts’ collective prediction of bio-
chemical and CR-POPF. In our current assessment, the c-statistic
improved when predicting the overall occurrence of fistula rather
than only CR-POPF. As biochemical fistulae have no clinical
impact, the benefit derived from their pre-operative prediction is
questionable. An advantage of pre-operative risk assessment is the
ability to provide informed consent to the patient regarding their
operative risk for morbidity and mortality. If a surgeon informs a
patient that they have a high risk for fistula development, yet is
unable to say whether the fistula would be innocuous or clinically
impactful, what is the benefit of such a prediction or consent
process? In this external assessment, predicting any type of fistula,
rather than just CR-POPF, predicted 52.3% more patients to have
a fistula when one actually occurred; however, 13% more patients
developed a fistula when one was not predicted. Striking the right
balance between PPV and NPV is not a simple process, but a risk
model must have a high NPV when ruling out patients for signifi-
cant complications.
Next, the prediction of POPF is inadequate when only pre-
operative variables are considered.While pre-operative prediction
may have a role in counselling, we do not believe it realistically
influences surgical decision making. Do we really decide not to
provide a resection to a patient because they have a defined risk of
this single, usually manageable, complication? We believe infor-
mation obtained at the point of anastomotic reconstruction is
relevant for predicting anastomotic failure. This is reflected by the
importance of intra-operative blood loss as a contributor to
CR-POPF risk.5 Furthermore, BMI and other measurements of
pancreatic adiposity only estimate pancreatic texture.We contend
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that this risk factor is most accurately assessed intra-operatively by
an experienced pancreatic surgeon.
To conclude, although pre-operative risk assessment may offer
some value, it should not be implemented at the cost of predictive
capacity, particularly if the score is also used for comparative
research or performance assessment. Previously validated fistula
risk metrics, which include intra-operative criteria, should not be
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